ABSTRACT A 71 year old patient developed a supraventricular tachycardia after the administration of nebulised ipratropium bromide.
11-2 kPa; Paco2 5 3 kPa) was referred for consideration of domiciliary nebuliser treatment. Her usual medications were prednisolone 10mg daily, inhaled beclomethasone 2 mg daily, inhaled salbutamol 800 pg daily, inhaled ipratropium bromide 160 pg daily, and slow release theophylline 400 mg at bedtime. She also took amiloride 5 mg and hydrochlorothiazide 50 mg daily for mild ankle oedema. She was given a test dose of ipratropium bromide (0 5 mg of preservative free solution in 2 ml saline by nebuliser) in the outpatient clinic with no adverse effects, so she was prescribed 05 mg nebulised ipratropium bromide to be taken four times a day at home. She reattended the following day because severe breathlessness began a few minutes after completion of each dose and lasted two to three hours. She was too distressed to record her peak flow rate. She was admitted for further assessment.
Her initial treatment was 5 mg salbutamol nebuliser solution by inhalation six hourly. She complained ofepisodic breathlessness with this treatment, however, despite a moderate rise in her peak flow. An electrocardiogram recorded during such an episode showed the development of atrial fibrillation (152 beats/min). Her baseline ECG showed sinus rhythm (104 beats/min with three supraventricular ectopic beats/min), right atrial hypertrophy, and minor repolarisation changes. Urea and electrolyte concentrations were normal and the morning serum theophylline concentration was 99 pmol/l (target range 55-110 
Discussion
Previous laboratory studies have suggested that inhaled ipratropium bromide does not cause any increase in heart rate.' Nebulised ipratropium bromide (0 5 mg) had no effect on the heart rate of seven asthmatic and 13 bronchitic patients we have studied (personal observation 
